Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Luoxin Pharmaceutical
Linyi, Shandong, Chinaluoxin.cn ↗
- Ownership
- Private
- Employees
- ~5500
- Development stage
- Other
01
Overview
Luoxin Pharmaceutical is a top-100 Chinese pharma company with >300 marketed products and a robust pipeline. It has achieved commercial success with multiple generic and novel small molecule and biologic drugs. Recent clinical results include a Phase 3 trial for a potassium-competitive acid blocker (LXI-15028) meeting its primary endpoint in erosive esophagitis and ongoing co-development of a third-generation EGFR inhibitor for NSCLC with Yuhan[1][8].
- Therapeutic areas
- EndocrinologyInfectious DiseasesGastroenterologyPulmonologyCardiovascularOncologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Pharma
02
Partnerships
Marinomed Biotech AGAurobindo PharmaYuhanTeikoku Pharma USAJW Holdings
Beyond the preview
Go deeper on Luoxin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luoxin Pharmaceutical.